Spago Nanomedical
0.341 SEK -4.75%Be the first to follow this company
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Revenue
1.2M
EBIT %
-3,589.17 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPAGO
Daily low / high price
0.315 / 0.349
SEK
Market cap
76.63M SEK
Turnover
46.34K SEK
Volume
136K
Financial calendar
General meeting
10.06.2024
Interim report
21.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Lindell | 40.5 % | 40.5 % |
Mikael Lönn | 8.5 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Spago Nanomedical interim report January-March 2024
Spago Nanomedical reports favorable data in breast cancer model with Tumorad
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools